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Abstract
Mitotane is the only drug approved for the therapy of adrenocortical carcinoma (ACC). 
Its clinical use is limited by the occurrence of relapse during therapy. To investigate the 
underlying mechanisms in vitro, we here generated mitotane-resistant cell lines. After long-
term pulsed treatment of HAC-15 human adrenocortical carcinoma cells with  
70 µM mitotane, we isolated monoclonal cell populations of treated cells and controls 
and assessed their respective mitotane sensitivities by MTT assay. We performed exome 
sequencing and electron microscopy, conducted gene expression microarray analysis and 
determined intracellular lipid concentrations in the presence and absence of mitotane. 
Clonal cell lines established after pulsed treatment were resistant to mitotane (IC50 of 
102.2 ± 7.3 µM (n = 12) vs 39.4 ± 6.2 µM (n = 6) in controls (biological replicates, mean ± s.d., 
P = 0.0001)). Unlike nonresistant clones, resistant clones maintained normal mitochondrial 
and nucleolar morphology during mitotane treatment. Resistant clones largely shared 
structural and single nucleotide variants, suggesting a common cell of origin. Resistance 
depended, in part, on extracellular lipoproteins and was associated with alterations in 
intracellular lipid homeostasis, including levels of free cholesterol, as well as decreased 
steroid production. By gene expression analysis, resistant cells showed profound 
alterations in pathways including steroid metabolism and transport, apoptosis, cell growth 
and Wnt signaling. These studies establish an in vitro model of mitotane resistance in 
ACC and point to underlying molecular mechanisms. They may enable future studies to 
overcome resistance in vitro and improve ACC treatment in vivo.
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Introduction
ACCs are rare and aggressive malignancies of the adrenal 
cortex, with an annual incidence of 0.7–2.0 cases per 
million population (1). ACCs can be part of rare hereditary 
cancer syndromes including Beckwith-Wiedemann 
syndrome (with alterations of imprinted genes on 
chromosome 11p15.5) and Li-Fraumeni syndrome (with 
mutations in TP53) (2), but most cases are sporadic. ACCs 
can develop at any age, with a peak incidence between 40 
and 50 years of age, and women are more often affected 
(55–60%) (1). Patients typically present with symptoms 
of hormone excess in the case of secretory tumors or 
otherwise with large tumors and signs and symptoms of 
malignancy.
Complete surgical resection is the only potentially 
curative treatment option for ACCs. Although 
the majority of patients have resectable disease at 
presentation, up to 85% relapse after radical resection 
(3), leading to an overall poor prognosis. Mitotane, a 
by-product of the industrial production of the insecticide 
dichlorodiphenyldichloroethane, has been widely used 
in ACC therapy due to its adrenolytic properties (4, 
5). A retrospective study demonstrated an association 
of adjuvant mitotane with prolonged recurrence-free 
survival after radical resection (6); however, results of 
a randomized controlled trial (ADIUVO) remain to be 
published (1). The randomized controlled FIRM-ACT 
trial found better response rates (23 vs 9 %) and median 
progression-free survival (5 vs 2.1 months) on mitotane 
combined with etoposide, doxorubicin and cisplatin 
(EDP-M) than with streptozotocin (7), with no significant 
difference in overall survival (14.8 vs 12 months). Hence, 
EDP-M is typically considered a first-line cytotoxic 
treatment for ACCs.
While mitotane plasma levels affect response rates, 
some patients do not respond despite therapeutic plasma 
levels. More importantly, patients who initially respond 
typically relapse even though therapeutic mitotane levels 
are maintained (8), suggesting a role of secondary acquired 
resistance to mitotane in relapse and progression.
The molecular changes associated with mitotane 
treatment have been examined in the human cancer cell 
lines H295R (9) and SW13 (10). Cytotoxic effects are visible 
at therapeutic mitotane concentrations (30–50 µM), 
and mitochondrial disruption appears to activate 
apoptosis through caspase 3/7, accounting for cytotoxicity 
(11). Effects also include a decrease in the expression of 
mitochondrial genes involved in steroidogenesis, such 
as STAR, CYP11B1 and CYP11B2, and a reduced activity 
of cytochrome c oxidase (12). More recently, inhibition 
of the microsomal sterol-o-acyl transferase 1 (SOAT1, 
also known as ACAT-1) has been suggested as the 
principal mode of action (13). Because SOAT catalyzes 
the generation of cholesterol esters from free sterol and 
acyl CoA (14), inhibition of its activity has been proposed 
to result in elevated levels of free cholesterol, ER stress 
and apoptosis. The molecular mechanisms of acquired 
mitotane resistance, however, are currently unknown. We 
here set out to generate a mitotane-resistant cell line to 
study mechanisms of mitotane resistance in vitro.
Materials and methods
Cell culture
HAC-15 cells (obtained from the Department of Molecular 
and Integrative Physiology, University of Michigan, Ann 
Arbor, MI, USA; authenticated by short tandem repeat 
analysis (LGC Standards, Wesel, Germany)) were cultured 
at 37°C and 5% CO2 in DMEM/F-12 + GlutaMAX (Gibco, 
Thermo Fisher Scientific) supplemented with 5% Cosmic 
Calf Serum (CCS, Hyclone, Logan, UT, USA), 1% Insulin-
Transferrin-Selenium, 1% MEM non-essential amino 
acids, 0.1% chemically defined lipid concentrate and 1% 
Penicillin (10,000 U/mL)/Streptomycin (10,000 µg/mL) 
(Gibco).
Compounds
Compounds were dissolved as follows and stored as stock 
solutions at -20°C: mitotane (Sigma Aldrich), 100 mM in 
DMSO; doxorubicin (Cayman Chemical), 1 µM in HAC-
15 medium; human HDL and LDL (Cedarlane, Burlington, 
Canada), 10 mg/mL in 15% sucrose (Carl Roth, Karlsruhe, 
Germany)/DMEM/F-12, HEPES (Gibco).
Long-term mitotane treatment of HAC-15 cells and 
clonal selection
Cells were frozen in aliquots as founder cells for reference. 
HAC-15 cells (starting from passage 4) were treated with 
70 µM mitotane (about 1.5-fold the IC50) following a 
pulsed protocol (15). Medium was replaced every 3–4 
days. At medium changes, cells alternately received either 
mitotane-free medium or medium containing 70 µM 
mitotane. Control cells received mitotane-free medium 
or medium containing solvent. At each passage, 107 cells 
were seeded in 75 cm² EasYFlasks (Nunc, Thermo Fisher 
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Scientific), and treatment was continued after 24 h. For 
clonal selection, cells were plated on a 15 cm cell culture 
dish (VWR International, Radnor, PA, USA) at a density 
of 56 cells/cm2 without mitotane and isolated using 
cloning discs (Sigma Aldrich) with Trypsin-EDTA (0.05%, 
Gibco). After cloning, treatment with 70 µM mitotane 
was resumed.
Growth curves
At each passage, cells were counted using a JuLI Br Live 
Cell Imager (NanoEnTek, Seoul, Korea), and cumulative 
population doublings (cPD) (16) were calculated from 
total cell numbers using Eq. 1:
cPD cPD log
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cPDL, cumulative population doublings after the last 
passage; NC, number of cells counted at the current 
passage; NS, number of cells seeded after the last passage.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay
After discontinuation of mitotane treatment (if applicable) 
for at least 2 weeks, 4 × 104 cells/well were seeded in 
triplicates on a 96-well plate (Gibco). After 24 h, cells 
were treated with cytotoxic compounds at 37°C for 72 h. 
Afterwards, a 5 mg/mL solution of MTT (Sigma Aldrich) 
in PBS was added to each well (final concentration 
0.45 mg/mL), followed by incubation at 37°C for 2 h. 
Medium was removed, and MTT crystals were dissolved in 
150 µL 10% Triton X-100 (Sigma Aldrich) in 2-propanol 
at pH 4.7. Absorption at 595 nm was recorded utilizing 
an EnSpire 2300 Multilabel Reader (PerkinElmer). For 
calculation of IC50, data were fitted to a four-parameter dose-
response curve with Prism 7 (GraphPad) according to Eq. 2:
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Y, absorption at 595 nm; A, minimum asymptote; B, 
maximum asymptote; IC50, half-maximal inhibitory 
concentration; X, log10 transformed mitotane 
concentration; HS, Hill slope.
For determination of response to different sera, cells 
were grown in the presence of 5% CCS, 2.5% CCS, 5% 
Nu-Serum (NuS, Corning) and 2.5% NuS or 5% fetal calf 
serum (FCS, Merck-Biochrom, Berlin, Germany). After 
24 h, MTT assay was performed as mentioned previously. 
Serum concentrations of cholesterol, HDL, LDL and 
triglycerides were determined by photometry at the 
Central Laboratory of the University Hospital Düsseldorf, 
Germany, and concentrations of compounds in the 
culture medium were calculated. All groups were tested 
for normality using Shapiro–Wilk test. Concentrations of 
lipid species were plotted against their respective IC50, and 
correlation analysis according to Pearson was performed 
using Prism 7.
Measurement of intracellular lipids
Intracellular lipids were determined in three nonresistant 
and three mitotane-resistant clones. Cells were seeded 
on a six-well plate. After 24 h, one group of cells was 
treated with vehicle control (DMSO) or 10 µM mitotane 
in medium containing 0% CCS for 72 h. A second 
group was treated with DMSO, 20 or 50 µM mitotane in 
medium containing 5% CCS for 72 h. Cells were washed 
thrice with cold PBS and lysed in 1 mL water containing 
0.1% sodium dodecyl sulfate (SDS, Biomol, Hamburg, 
Germany). Protein content was measured by BCA Protein 
Assay Kit (Pierce). Lipids were measured by electrospray 
ionization tandem mass spectrometry (ESI-MS/MS) and 
normalized to total protein quantity in mg, as previously 
described (17).
Measurement of supernatant steroid hormones
Cells were seeded on a 12-well plate. After 48 h, medium 
was replaced. After 24 h, cell supernatants were removed 
and quickly frozen at -80°C. Steroid analysis was performed 
by liquid chromatography tandem mass spectrometry 
(LC-MS/MS) as described elsewhere (18); testosterone, 
dihydrotestosterone, 18-hydroxycorticosterone, 
11-dehydrocorticosterone and dexamethasone were 
added to the panel (Supplementary Table 1, see section on 
supplementary materials given at the end of this article).
In brief, 0.45 mL of cell culture supernatants were 
processed via solid phase extraction using positive pressure, 
dried down and finally reconstituted in 100 µL of initial 
LC mobile phase. For quantification of steroid hormones, 
regression analyses using respective analyte peak areas 
relative to those of respective internal standards vs analyte 
concentrations derived from an external calibration were 
used. Such ratios observed in samples were further used to 
quantify steroid hormone concentrations by applying the 
respective regression equations.
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Statistics
Data were tested for normality using Shapiro–Wilk test. 
Data passing the normality test were compared using an 
unpaired t-test (two-tailed) or one-way ANOVA (multiple 
comparisons), and groups failing the normality test were 
compared using a Mann–Whitney test or Kruskal–Wallis 
test (multiple comparisons). As post hoc test, two-stage 
Benjamini, Krieger and Yekutieli FDR procedure was used.
Gene expression microarray
Six nonresistant and six mitotane-resistant clones were 
thawed and cultured to confluence without mitotane. 
Cells were seeded on a six-well plate (1 × 106 cells per well). 
After 24 h, cells were treated with either vehicle control 
(DMSO) or 50 µM mitotane for 18 h. RNA was isolated 
using QIAzol Lysis Reagent, miRNeasy MiniKit and RNase-
Free DNase set (all from Qiagen), and RNA integrity was 
confirmed using an Agilent 2100 Bioanalyzer. Microarrays 
were processed at the Center for Applied Genomics at 
the Hospital for Sick Children (Toronto, Canada) using 
Affymetrix GeneChip PrimeView Human Gene Expression 
Array. Microarray analysis was performed in R (version 
3.4.4) using the packages affy, affydata and limma. Pre-
processing was done using expresso with rma background 
correction (19), quantile normalization, pmonly probe 
specific correction and avgdiff summarization. Log-
transformed normalized intensities were used for principal 
component analysis (PCA) using the prcomp R function. 
Differential expression was performed with limma and a 
blocking design to match treated and untreated cell lines. 
Differentially expressed genes were extracted from top-
expressed probe sets after Benjamini–Hochberg correction 
using a cutoff of 5% on the adjusted P-value and of 0.5 
on the log2 fold change. GO term analysis (20) was 
performed using topGO, using the classic algorithm and 
a cutoff of 0.01 on the Fisher P value. Expression changes 
were compared to copy number changes by aggregating 
CNV results per gene and calculating log2 fold change 
in read depth relative to the control. Microarray data 
is available at the Gene Expression Omnibus database 
(GEO accession# GSE140818).
Whole exome sequencing and analysis
DNA from the founder line, one nonresistant and six 
resistant clones (identical to those used for gene expression 
microarrays), was isolated using the DNeasy Blood & 
Tissue Kit (Qiagen). Whole-exome capture using SeqCap 
EZ Med Exome (Roche) and high-throughput sequencing 
(HiSeq 4000, Illumina) were performed at the Yale Center 
for Genome Analysis.
We used BWA-mem v0.7.15 (21) to map each whole-
exome data set against genome reference GRCh37(hs37d5.
fa). Separate read groups were assigned for all reads from 
one lane, and duplicates were masked using Samblaster 
v0.1.24 (22). Copy number alterations were analyzed 
in a tumor/normal paired fashion with the R package 
CopywriteR (23) with 50 kb bins and annotated with the 
CIViC database (24), where we treated the founder cell lines 
as normal and the resistant cultures or control as tumor 
sample. All log2 fold changes denote the relative change 
in read-depth compared to the founder cell line. Single 
nucleotide variants were called with MuTect (25) with the 
default configuration. Variants were filtered for artifacts 
using dkfz-bias-filter and annotated with Jannovar v0.24 
(26). Candidate SNVs were manually assessed using the 
Integrative Genomics Viewer (IGV_2.4.13, Broad Institute).
Electron microscopy
For transmission electron microscopy, two resistant and 
two nonresistant clones were thawed and cultured to 
confluence without mitotane. Cells were seeded on a 
6-well plate (2 × 106 cells per well). After 24 h, cells were 
treated with 50 µM mitotane or vehicle control (DMSO). 
After 72 h, cells were washed once with ice cold PBS 
and fixed with 2.5% glutaraldehyde in 0.1 M sodium 
cacodylate buffer (both from Serva, Heidelberg, Germany) 
at room temperature for 30 min. Afterwards, fixation 
buffer was changed, and cells were stored at 4°C for 2–14 
days. Cells were postfixed in 1% OsO4 (Science Services, 
Munich, Germany) and 0.8% potassium ferrocyanide 
(Merck) in 0.1 M sodium cacodylate buffer for 1.5 h 
and then progressively dehydrated in ethanol, followed 
by embedding in Epon (Serva). Ultrathin sections 
(70 nm) were prepared using an Ultracut S Ultramicrotome 
(Leica), stained with uranyl acetate and Reynold’s lead 
citrate (Merck), and microphotographs were taken using 
an electron microscope EM906 (Carl Zeiss).
Results
Generation, morphology and doxorubicin 
sensitivity of mitotane-resistant HAC-15 cell clones
HAC-15 cells showed a sigmoidal dose response to 
mitotane, with an IC50 of 46.4 ± 13.1 µM (mean ± s.d., n = 3) 
(Supplementary Fig. 1). We performed pulsed treatment of 
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the founder line with 70 µM mitotane to induce resistance 
(15) (Fig. 1A, see Materials and methods). MTT assays 
revealed an IC50 of 102.2 ± 7.3 µM for resistant clones 
(n = 12, biological replicates) and 39.4 ± 6.2 µM for control 
clones (mean ± s.d., n = 6, biological replicates, P = 0.0001, 
Mann–Whitney test), demonstrating significant mitotane 
resistance in treated clones (Fig. 1B).
To assess whether mitochondrial integrity was 
preserved in resistant cells, we treated resistant cells and 
controls with 50 µM mitotane and performed electron 
microscopy (Fig. 2, Supplementary Fig. 2). Untreated 
nonresistant (Fig. 2A, B and C) and resistant clones (Fig. 
2G, H and I) displayed normal cellular and mitochondrial 
morphology with frequent mitoses. In nonresistant cells, 
mitotane treatment caused mitochondrial swelling with 
loss of cristae as previously described (11). Additional 
morphological changes included irregular nuclear shapes 
(Fig. 2D, E and F) and large lipid droplets surrounded 
by concentric layers of rough endoplasmic reticulum 
(Supplementary Fig. 3), as well as necrotic cells and 
intracellular protein deposits. Interestingly, no such 
changes occurred in resistant cells upon mitotane 
treatment (Fig. 2J, K and L). The absence of mitochondrial 
damage in treated resistant cells specifically suggests that 
the mechanism of resistance in this model acts upstream 
of mitochondrial damage. We assessed doxorubicin 
sensitivity in six resistant and six nonresistant clones in 
the absence or presence of 10 µM mitotane. In the absence 
of mitotane, no significant difference in doxorubicin 
sensitivity between resistant and nonresistant cells was 
found (IC50 of 3.7 ± 0.6 nM and 4.6 ± 1.5 nM (mean ± s.d., 
n = 6 each, P = 0.12, one-way ANOVA)). In the presence 
of 10 µM mitotane, resistant clones showed increased 
doxorubicin sensitivity compared to controls (IC50 of 
2.2 ± 0.4 nM vs 3.9 ± 1.2 nM (mean ± s.d., n = 6 each, 
P = 0.0017, one-way ANOVA)) (Supplementary Fig. 4).
Pathways involving steroid metabolism and 
transport, apoptosis, cell growth and Wnt signaling 
are altered in mitotane-resistant cell lines
We compared gene expression profiles of six mitotane-
resistant with six nonresistant clones in the presence and 
the absence of mitotane (see Materials and methods). In 
PCA, resistant cell lines clustered separately from control 
cell lines, whereas response to mitotane was less uniform 
(Fig. 3A). Unbiased analysis identified 1581 differentially 
expressed genes between resistant cells and controls in the 
absence of treatment (see Materials and methods, Fig. 3B, 
Table 1, Supplementary Fig. 5 and Supplementary Table 
2). Genes with upregulated expression included AXIN2, 
a Wnt target gene (27), and IGF1, encoding an insulin-
like growth factor. IGFs have been implicated in adrenal 
development (28) and tumor formation (29). Genes with 
downregulated expression included SOAT1, encoding for 
sterol-o-acyl transferase 1, a major intracellular target 
of mitotane (13), and SCARB1, encoding for scavenger 
receptor B1, the most important transporter for adrenal 
cholesterol uptake (30). Further, downregulation of 
steroidogenic enzymes CYP11A1, encoding for cholesterol 
side-chain cleaving enzyme, HSD3B2, encoding for 
3β-hydroxysteroid dehydrogenase/Δ5-4 isomerase, 
CYP21A2, encoding for steroid 21-hydroxylase, and 
STAR, encoding for StAR protein, was discovered. STAR 
and CYP11A1 participate in rate-limiting steps in adrenal 
steroidogenesis, which include cholesterol uptake into 
the mitochondria and the conversion of cholesterol to 
pregnenolone (31). Upon mitotane treatment of control 
cells, 60 genes were differentially expressed. In accordance 
with a previous study (13), downregulation of SREBF1, 
encoding sterol regulatory binding transcription factor 1, 
was demonstrated. Also, expression of genes involved in 
Figure 1
(A) Growth curves of HAC-15 cells during long-term treatment with 
mitotane vs untreated control. Every 3–4 days, cells were treated with  
70 µM mitotane in on-off cycles. The total number of population 
doublings (cumulative population doublings; cPD) is indicated. During 
long-term treatment, cells initially died, but the population recovered 
after approximately 30 days. (B) IC50 of mitotane in 12 clones derived 
from long-term treated HAC-15 cells vs 6 control clones measured by MTT 
assay after 72 h of incubation. Results are shown in scatter dot plots with 
mean ± s.d. ***, P < 0.001 (Mann–Whitney test).
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endoplasmic reticulum stress response was significantly 
altered, including upregulation of DDIT3, encoding 
DNA damage-inducible transcript 3, XBP1, encoding 
X-box binding protein 1, and GDF15, encoding growth/
differentiation factor 15 (Table 1) (32, 33). Interestingly, 
treatment of resistant cells did not yield any differentially 
expressed genes above the log2 fold change cutoff of 0.5, 
confirming resistance on the gene expression level.
To identify pathways involved in in vitro mitotane 
resistance, we performed gene ontology enrichment 
analysis. Untreated resistant cells showed significant 
upregulation of genes implicated in apoptosis regulation, 
whereas pathways related to steroid metabolism, 
regulation of ERK (extracellular signal-regulated kinases) 
cascade, apoptotic cell clearance and response to 
xenobiotics were downregulated (Supplementary Table 3). 
Mitotane treatment of control cells led to upregulation 
of pathways including cell death and unfolded protein 
response, whereas pathways related to lipid homeostasis 
and transport were downregulated (Supplementary Table 
4). These results are in line with the current concept of 
mitotane action via accumulation of free cholesterol and 
ER stress, leading to apoptosis (13), processes that are 
apparently mitigated in our in vitro model of resistance.
In vitro mitotane-resistant clones are genetically 
highly similar, suggesting a single cell of origin
To identify genetic mechanisms underlying mitotane 
resistance and to further characterize mitotane-resistant 
cell lines, we performed whole exome sequencing of six 
mitotane-resistant clones. As controls, we sequenced 
Figure 2
Representative electron micrographs of one 
nonresistant (A, B, C, D, E and F) and one resistant 
clone (G, H, I, J, K and L), treated for 72 h with 
either vehicle control (A, B, C, G, H and I) or 50 µM 
mitotane (D, E, F, J, K and L). Mitotane treatment 
causes mitochondrial swelling, loss of 
mitochondrial cristae and irregular nuclear 
shapes in nonresistant, but not in resistant cells. 
N: nuclei; *: mitochondria; LD: lipid droplet. Lines: 
5 µm (A, D, G and J); 2.5 µM (B, E, H and K);  
1.25 µm (C, F, I and L).
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International License.
https://doi.org/10.1530/EC-19-0510
https://ec.bioscientifica.com © 2020 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 02/12/2020 08:01:07AM
via free access
E Seidel, G Walenda et al. Mitotane resistance in an ACC 
cell line
1289:2
the founder cell line and one nonresistant clone. Cells 
cultured over extended periods of time are known to 
accumulate mutations (34). Remarkably, the CNV profiles 
of all six resistant lines differed from the control line, 
but were highly similar among each other, suggesting 
a single resistant cell of origin (Fig. 4A). Analysis of 
heterozygous calls for MTTP (c.3G>A, NM_000253.3) in 
an area of copy number loss on chromosome 4 shared 
between resistant lines and control demonstrated that 
different alleles had been lost in resistant cells and 
controls, respectively. Areas of gain shared among 
resistant cells included chromosomes 2, 3 and 4, whereas 
loss was detected uniformly on chromosomes 4, 5, 7, 
12, 13 and 15. Genes whose increased gene expression 
correlated with gain or whose decreased gene expression 
correlated with loss of chromosomal material (Fig. 4B) 
included PDGFC encoding platelet derived growth 
factor C involved in cell proliferation (35) and FBXW7, 
Figure 3
(A) PCA of gene expression for resistant and nonresistant cell lines treated with DMSO or mitotane. Corresponding cell lines are connected by lines, and 
percentage-explained variance is given in the axis title. (B) Expression heatmap of differentially expressed genes in any of four comparisons: resistant cell 
lines with vs without mitotane treatment (R.MvsD; no significant changes), nonresistant cell lines with vs without treatment (NR.MvsD), resistant vs 
nonresistant cell lines under treatment (RvsNR.M) or without treatment (RvsNR.D). Expression data were transformed to z-scores for standardization. 
Significantly changed genes (5% FDR, log2 fold change cutoff 0.5) are indicated by orange bars on the right, and selected genes are highlighted.
Table 1 Gene expression changes after mitotane treatment of control cells or after development of resistance (selection).
Gene Log2 FC Exp Adj P Comparison
SCARB1 −2.54 7.76 2.4 × 10−20 Resistant DMSO vs Nonresistant DMSO
HSD3B2 −5.77 5.33 5.98 × 10−18 Resistant DMSO vs Nonresistant DMSO
CYP11A1 −3.66 6.45 1.01 × 10−17 Resistant DMSO vs Nonresistant DMSO
CYP21A2 −4.34 6.61 7.49 × 10−17 Resistant DMSO vs Nonresistant DMSO
IGF1 4.24 5.74 2.94 × 10−14 Resistant DMSO vs Nonresistant DMSO
STAR −3.52 7.14 4.17 × 10−14 Resistant DMSO vs Nonresistant DMSO
AXIN2 1.59 6.87 2.2 × 10−13 Resistant DMSO vs Nonresistant DMSO
SOAT1 −1.95 7.35 1.64 × 10−12 Resistant DMSO vs Nonresistant DMSO
DDIT3 1.55 5.94 2.55 × 10−8 Nonresistant Mitotane vs Nonresistant DMSO
GDF15 1.87 5.9 8.19 × 10−6 Nonresistant Mitotane vs Nonresistant DMSO
SREBF1 −1.14 6.16 8.4  × 10−6 Nonresistant Mitotane vs Nonresistant DMSO
XBP1 0.75 6.96 7.29 × 10−4 Nonresistant Mitotane vs Nonresistant DMSO
Only genes referenced in results section are listed.
Adj P, adjusted P value; DMSO, dimethyl sulfoxide; Exp, average expression; Log2 FC, log2 fold change.
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which can apparently function as a tumor suppressor or 
as an oncogene (36) (both upregulated). UBE2QL1, whose 
gene product interacts with FBXW7 and is considered a 
tumor suppressor (37), was downregulated, as were FBXL7 
involved in impairing cell proliferation (38), TNFRSF1A 
and LTBR, encoding TNF receptors involved in apoptosis.
In vitro mitotane-resistant cells have a higher 
burden of protein-changing SNVs than control cells
Next, we identified SNVs acquired as part of the 
development of mitotane resistance by comparing exomes 
of resistant cell lines and controls. In the six resistant 
clones, we respectively identified 19, 21, 23, 16, 26 and 19 
newly acquired potentially protein-changing mutations 
that were absent in the founder line. In contrast, only 
nine newly acquired mutations were detected in the 
nonresistant cell line, suggesting a higher mutational 
burden in treated cells as a result of selection. Eleven 
newly acquired mutations shared among all resistant 
cell lines are shown in Table 2. Affected genes include 
PLCH1, encoding a member of the phospholipase C (PLC) 
family (39), PLXNB1, encoding plexin B1 implicated in 
invasive growth and cell migration (40), LRP4, a potential 
negative regulator of Wnt signaling (41) and GNL3, which 
may interact with p53 and appears to be involved in 
tumorigenesis (42).
Mitotane-resistant cells show profoundly altered 
intracellular lipid profiles
Because microarray analysis had revealed alterations in 
pathways governing lipid homeostasis, we measured 
intracellular levels of several lipid species in three mitotane-
resistant and three nonresistant clones, each treated 
with 0 or 10 µM mitotane in the absence of serum (high 
availability of free mitotane) or 0, 20 and 50 µM mitotane 
in the presence of 5% cosmic calf serum (CCS) (lower 
availability of free mitotane due to lipoprotein binding). 
In line with the proposed inhibitory effect of mitotane on 
SOAT1 (13), treatment of nonresistant cells with 50 µM 
mitotane resulted in increased levels of free cholesterol, 
whereas this effect was absent in resistant cells. Levels 
of cholesteryl esters did not significantly change upon 
treatment with 50 µM mitotane in either nonresistant 
or resistant clones (Fig. 5A, B and Supplementary Table 
5, 6). Levels of ceramides, a lipid species with a well-
established role in apoptotic signaling (43, 44), also 
significantly rose in nonresistant cells after treatment 
with 50 µM mitotane, an effect that was again mitigated 
in resistant cells, and levels of lysophosphatidylcholines, 
which have been implicated in lipoapoptosis (45), were 
significantly higher in nonresistant cells treated with 
50 µM mitotane (Supplementary Fig. 6 and Supplementary 
Tables 5, 6). Prior studies (46, 47) suggested that mitotane 
cytotoxicity may be influenced by cholesterol-bearing 
Figure 4
(A) Copy number changes compared to founder cell line. Whole-exome sequencing data of resistant and nonresistant cell lines were compared to the 
founder cell line in a tumor/normal matched pair fashion to analyze copy number changes. Log2 fold changes are shown across the genome. Resistant 
cell lines share CNV patterns that are distinct from the control, suggesting a common cell of origin of resistant clones. (B) Comparison of average CNV to 
gene expression changes (resistant vs nonresistant cells). Top panel shows CNV log2 fold change per gene across the genome. Bottom panel shows log2 
fold change in RNA expression between resistant and nonresistant clones (without mitotane treatment). Selected genes with consistent log2 fold changes 
(|CNV| > 0.5, |RNA| > 1, CNV*RNA > 0) are highlighted. Orange lines indicate smooth moving average. The overall correlation is 0.28. Chr, chromosome.
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lipoproteins such as LDL and HDL. In the presence of 
artificially low lipoprotein levels (0.005 mg/mL HDL, 
0.005 mg/mL LDL), median IC50 of not only nonresistant 
but also resistant cells dropped significantly compared to 
more physiological levels (0.05 mg/mL HDL, 0.05 mg/mL 
LDL) (Supplementary Fig. 7).
Mitotane-resistant cells show impaired production 
of adrenal steroid hormones
Next, we measured levels of adrenal steroid hormones 
in cell supernatants of founder cells, nonresistant and 
resistant cells by LCMS (Fig. 6). Steroid profiles of the 
founder cell line and nonresistant clones were largely 
comparable and included abundant levels of cortisol 
and moderate levels of aldosterone as well as very small 
amounts of DHEA. In resistant clones, steroid hormone 
production was strongly reduced. Aldosterone and cortisol 
were only detected at low levels in one of three clones.
Discussion
To our knowledge, this study is the first to establish 
an in vitro model of mitotane resistance in ACC along 
with nonresistant controls. We chose the HAC-15 cell 
line as an ideal candidate for this study based on its 
production of adrenal steroid hormones and clonality 
(48). Although originally described as a new primary 
adrenocortical cell line, HAC-15 cells are now considered 
a clonal subpopulation of the most commonly used 
H295R adrenocortical cancer cell line (48). Another 
commonly used cell line, SW13 (10) may be derived from 
a metastasized non-adrenal tumor (48) and seemed less 
useful due to its lack of steroid production. The mitotane 
sensitivities of two very recently established ACC cell 
lines remain to be determined (49). A recently established 
xenograft model shows mitotane resistance (50); however, 
the lack of a nonresistant control prevented its use in 
this study.
Table 2 Variants shared among all resistant cell lines.
Gene Protein Change Chr Pos Ref Var
CD34 T89K 1 208072568 G T
FLNB D1264Y 3 58110124 G T
LRP4 N138S 11 46921431 T C
PLXNB1 A838S 3 48461183 C A
HOMER3 G78V 19 19049232 C A
PLCH1 N856S 3 155205833 T C
PRSS50 V98I 3 46758942 C T
PDE12 R23W 3 57542173 C T
SLCO1B7 R11I 12 21168661 G T
ABHD14A-ACY1 predicted splice site mutation 3 52011879 C T
GNL3 V367M 3 52727257 G A
Chr, chromosome; Pos, chromosomal position, Ref, reference base; Var, variant base.
Figure 5
Intracellular lipds in three mitotane-resistant vs three nonresistant HAC15 clones. (A) Amounts of phosphatidylcholine, sphingomyelin, 
phosphatidylethanolamine, phosphatidylethanolamine (PE) based plasmalogens, phosphatidylserine, phosphatidylionositol, lysophosphatidylcholine, 
ceramide, cholesteryl ester and free cholesterol after treatment with increasing concentrations of mitotane in presence of different serum 
concentrations. (B) Amounts of saturated, monounsaturated, polyunsaturated, total unsaturated and total cholesteryl ester (CE) as well as free 
cholesterol (FC), determined as in (A). Treatment with 50 µM mitotane in presence of 5% CCS increases free cholesterol in nonresistant cells but not in 
mitotane-resistant cells. For lipid amounts and statistical analysis, please refer to Supplementary Tables 5 and 6.
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The clonality of the HAC-15 cell line, the long time 
span from the beginning of pulsed treatment to the 
recovery of growth, the highly similar genetic profiles 
of obtained mitotane-resistant cell clones and the high 
mutation burden all suggest that the mitotane-resistant 
cells described here are not derived from a pre-existing 
resistant subpopulation but rather arose through 
mutagenesis under selection. Consistently, prior efforts to 
isolate side populations from H295R cells did not yield 
resistant cells (51).
Prior studies have focused on the short-term response 
of H295R cells to mitotane, effects largely replicated in 
short-term treatment of control cells in our study. Our 
microarray data demonstrated downregulated expression 
of genes involved in steroid hormone pathways and 
upregulation of unfolded protein response genes, in line 
with previous data (11, 12, 13). The lower number of 
differentially expressed genes in our study may be related 
to different treatment durations (6 h in the study by Sbiera 
et al. vs 18 h in our study).
The focus of this study, however, was on in vitro 
mechanisms of mitotane resistance. Morphological 
analysis demonstrated that mitochondrial damage, a 
distinctive feature of mitotane-treated H295R cells (11), 
was absent in mitotane-treated resistant cells. These 
findings suggest that altered pathways are located 
upstream of mitochondrial damage. Accordingly, both 
gene expression analysis and functional studies pointed 
to changes in lipoprotein and lipid homeostasis. By 
gene expression microarray, we found downregulation 
of pathways implicated in steroid metabolism, but also 
regulation of ERK, apoptotic cell clearance and response 
to xenobiotics, which collectively may contribute to 
the resistant phenotype. Changes in copy number that 
correlated with gene expression changes were not related 
to mitotane signaling, suggesting that regulation of gene 
expression rather than CNV may play a role.
Unlike in nonresistant controls, intracellular free 
cholesterol – a major mediator of mitotane-associated 
apoptosis (13) – remained unchanged in resistant cells upon 
mitotane treatment. We confirmed data from Hescot et al. 
and Kroiss et al. demonstrating that lipoprotein binding 
inhibits mitotane activity in vitro (46, 47). Importantly, 
removal of extracellular lipoproteins in our study had a 
larger effect on the sensitivity of resistant cells than of 
nonresistant cells. If similar mechanisms are present 
in vivo, lowering the lipoprotein concentration could be 
a promising approach to overcome resistance (see below). 
Interestingly, mass spectrometry demonstrated strong 
downregulation of adrenal steroid production in vitro 
in resistant cells, thus, it would be interesting to assess 
whether any reduction in hypercortisolism is sustained 
in vivo after the development of resistance.
Limitations of our study include the use of an in vitro 
cell model, which does not reflect the three-dimensional 
tumor architecture (52) or its microenvironment (53) 
and does not account for metabolism and excretion of 
mitotane or storage in fat-containing tissues (54). Ideally, 
our studies should be complemented by in vivo studies 
of mitotane resistance, comparing tumor material before 
mitotane therapy and after resistance has developed. 
However, such studies are challenging due to the rarity of 
ACCs and in particular of cases who undergo resurgery after 
the development of mitotane resistance. Furthermore, our 
results should be interpreted with caution because only a 
single cell line was studied.
Potential strategies to overcome mitotane resistance 
include SOAT inhibitors such as ATR-101 (55), inhibition 
of ER chaperones (56) or proteasome inhibitors (57). Of 
note, in our model, doxorubicin was more effective in 
resistant cells treated with mitotane than in nonresistant 
controls, an observation that so far remains unexplained. 
If applicable in vivo, these results would support the use 
of mitotane plus doxorubicin in case of relapse during 
mitotane monotherapy (as part of EDP-M (4)).
As discussed previously, in our cell model, mitotane 
resistance could be partially reversed by lowering 
extracellular lipoprotein concentrations. This effect is 
of particular importance because mitotane therapy can 
cause an increase in lipoprotein levels (58), potentially 
promoting resistance. Lowering lipoprotein levels through 
statin therapy has already been suggested to be associated 
with higher rates of tumor control during mitotane 
treatment (46). Novel PCSK9 inhibitors could be more 
promising given their ability to lower LDL levels beyond 
Figure 6
Supernatant steroid concentration normalized by total protein in the 
founder HAC15 cell line vs mitotane-resistant and nonresistant HAC15 
clones, determined by LC-MS/MS (n = 3). Steroid hormone production is 
largely abated in mitotane-resistant clones. Shown is mean ± s.d., 
(measured in triplicate) each from three clones, except for aldosterone 
and cortisol in resistant cells, for which results from a single clone are 
shown (levels from the two other clones were below detection limit). 
DHEA, dehydroepiandrosterone.
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statin therapy (59). Thus, we suggest that the model 
we here established might help to develop strategies to 
overcome mitotane resistance in vitro, which could then 
be further investigated in clinical trials.
Supplementary materials
This is linked to the online version of the paper at https://doi.org/10.1530/
EC-19-0510.
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